Usher Syndrome,Usher Syndrone, Sustained topical dorzolamide therapy improves visual acuity and reduces central foveal zone thickness in some patients with retinitis pigmentosa or Usher syndrome, according to a study in the September issue of the Archives of Ophthalmology.
In a retrospective case series, Mohamed A. Genead, M.D., and Gerald A. Fishman, M.D., of the University of Illinois at Chicago, evaluated 64 eyes of 32 patients with retinitis pigmentosa or Usher syndrome undergoing treatment with topical dorzolamide hydrochloride, 2 percent, for six to 58 months.
The investigators found that 20 patients (63 percent) had a positive response to treatment in at least one eye and 13 patients (41 percent) had a positive response in both eyes. However, four patients (20 percent) who experienced an initial response to treatment had a rebound of macular cysts.